Novo Nordisk A/s

Liselotte Langkjaer

Svend Havelund

Jan Markussen

Kjeld Norris

Elsebeth Norup

Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.

Formulations of insulin

Insulin analogs characterized by amino acid residue at A21 other than Asn, with a resulting improvement in stability of insulin solutions at acid pH levels. Some insulin analogs may also have amino acid residue changes elsewhere so that these insulin analogs exhibit at least about one charge more than human insulin at a pH value of 7, with preferred substitutions being made for the glutamic acid residues at A4, A17, B13, B21 and/or a basic amino acid residue being substituted at B27. Also contemplated is optional blocking the C-terminal carboxyl group of the B-chain with an amido or ester residue.

Growing community of inventors

Holte, Denmark

Liselotte Langkjaer